Oppenheimer analyst Wendy Lam reiterated an Outperform rating and $124 price target on Gilead Sciences (NASDAQ: GILD) following 'beat and ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst EPS Change Analyst EPS View

Gilead Sciences (GILD) raises Revenue Guidance Following 3Q Beat; Maxim Group Reiterates Buy October 28, 2015 1:47 PM Gilead Sciences (GILD) PT Raised at Cowen as HCV Sales Drive BeatOctober 28, 2015 8:53 AM Gilead (GILD) Slips Despite Strong Q3 ResultsOctober 27, 2015 4:13 PM Gilead Sciences (GILD) Tops Q3 EPS by 33c, Updates FY15 GuidanceOctober 27, 2015 4:02 PM